VHL and nonpapillary renal cell carcinoma: Table 1 provides an overview of the LITESPARK 004 and LITESPARK 005 studies. The rationale for the efficacy of belzutifan in ccRCC (independent of a VHL) is that most ccRCC tumours possess genetic or epigenetic alterations of the VHL gene [7,8].